Search

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
Strategic Partnerships
Creating pathways to LGMD genetic diagnosis: Spotlight on LGMD Grant Award recipient
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin
Community Letter: Community Update on LGMD Programs in Development
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics anuncia convocatoria de solicitudes para el 6.º Route 79 anual, el programa de becas Duchenne